Form 4: Neogenomics Executive Melody Harris Reports Stock and Option Grants
SEC Form 4 Filing
Melody Harris, Chief Operating Officer and President of Informatics at Neogenomics, reported the acquisition of restricted stock units and various stock options.
Summary
- Melody Harris, a key executive at Neogenomics, filed a Form 4 detailing changes in her beneficial ownership of company securities.
- The filing primarily covers the grant of restricted stock units and stock options, which vest over time and are subject to performance conditions.
- Ms. Harris received 59,382 restricted stock units on January 14, 2025, which vest over time.
- She also holds various stock options granted on different dates with exercise prices ranging from $9.24 to $19.65.
- Some of the stock options and restricted stock units vest ratably over the first three or four anniversary dates of the grant.
- Performance stock units are also included, with the number of shares that may vest dependent on the achievement of share growth and revenue goals.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management interests with shareholders. There are no indications of negative issues, but the value is dependent on future performance.
Positives
- The grants of stock options and restricted stock units align Ms. Harris's interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the executive.
- Performance-based stock units incentivize the achievement of specific company goals, such as share and revenue growth.
Risks
- The value of the stock options and performance stock units is dependent on the future performance of Neogenomics' stock price.
- The vesting of performance stock units is contingent on the company achieving specific share growth and revenue targets, which may not be met.
- The potential dilution of existing shares due to the issuance of new shares upon vesting of stock options and restricted stock units.
Future Outlook
The vesting of stock options and performance stock units is contingent on continued service with the company and the achievement of certain performance goals.
Industry Context
The granting of stock options and restricted stock units is a common practice in the biotechnology and healthcare industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are standard practice for executive compensation in the biotech industry, similar to companies like Exact Sciences (EXAS) and Guardant Health (GH).
- The vesting schedules, typically over three to four years, are also consistent with industry norms.
- Performance-based stock units are increasingly common, aligning executive compensation with company performance, similar to incentive plans at companies like Illumina (ILMN).
- The specific performance metrics, such as share growth and revenue targets, are tailored to Neogenomics' business goals, but the concept is widely used across the sector.
Stakeholder Impact
- Shareholders may view the grants positively as they align executive interests with company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership.
- The grants have no direct impact on customers or suppliers.
Next Steps
- The executive will continue to vest in the granted stock options and restricted stock units over the coming years.
- The company will monitor the achievement of performance goals related to the performance stock units.
Key Dates
| Date | Description |
|---|---|
| 01/01/2023 | Ms. Harris was granted 201,613 stock options. |
| 05/11/2023 | Ms. Harris was granted 39,683 stock options, 21,204 restricted stock units, and 21,204 performance stock units. |
| 02/23/2024 | Ms. Harris was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Ms. Harris was granted 19,984 stock options, 11,939 performance stock units, and 11,939 restricted stock units. |
| 01/14/2025 | Date of the earliest transaction reported, which includes the grant of 59,382 restricted stock units. |
| 01/13/2026 | Expiration date of the restricted stock units granted on 01/14/2025. |
| 05/11/2026 | Expiration date of the performance stock units granted on 05/11/2023. |
| 02/23/2027 | Expiration date of the performance stock units granted on 02/23/2024. |
| 05/02/2027 | Expiration date of the performance stock units granted on 05/02/2024. |
| 01/01/2030 | Expiration date of the stock options granted on 01/01/2023. |
| 05/11/2030 | Expiration date of the stock options granted on 05/11/2023. |
| 02/23/2034 | Expiration date of the stock options granted on 02/23/2024. |
| 05/02/2034 | Expiration date of the stock options granted on 05/02/2024. |
Keywords
Neogenomics, stock options, restricted stock units, performance stock units, executive compensation, insider trading, vesting, share growth, revenue growth
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.